Search

Your search keyword '"Chamuleau, Martine E.D."' showing total 31 results

Search Constraints

Start Over You searched for: Author "Chamuleau, Martine E.D." Remove constraint Author: "Chamuleau, Martine E.D." Publisher american society of hematology Remove constraint Publisher: american society of hematology
31 results on '"Chamuleau, Martine E.D."'

Search Results

1. Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphoma

2. Baseline PET radiomics outperform the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma

3. Therapies and Outcomes for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Contemporary, Nationwide, Population-Based Study in the Netherlands

4. Lenalidomide-Rituximab or Lenalidomide-Rituximab-Bendamustine in Patients with Relapsed/Refractory Follicular Lymphoma: Priimary Analysis of the Randomized Phase II HOVON110/Rebel Trial

5. Outcome of Transformed Marginal Zone Lymphoma: A Population Based Study

6. The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma

7. Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion

8. Genomic Landscaping of Post-Transplant Lymphoproliferative Disorders Using Circulating Tumor DNA

9. Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma

10. Special Anatomical Subtypes of Diffuse Large B-Cell Lymphoma Have Distinct Tumor Microenvironments

11. Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

12. External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

13. A Propensity Score-Adjusted Comparison of Lenalidomide + R-CHOP Versus R-CHOP for MYC-Rearranged DLBCL Patients

14. Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma

15. A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

16. High Grade B Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements Treated with DA-EPOCH-R Induction and Nivolumab Consolidation Treatment: Interim Results of the HOVON-152 Phase II Trial

17. Subcutaneous Epcoritamab Induces Complete Responses with an Encouraging Safety Profile across Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Subtypes, Including Patients with Prior CAR-T Therapy: Updated Dose Escalation Data

18. Duobody-CD3xCD20 Induces Potent Anti-Tumor Activity in Malignant Lymph Node B Cells from Patients with DLBCL, FL and MCL Ex Vivo, Irrespective of Prior Treatment with CD20 Monoclonal Antibodies

19. First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas

20. Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

21. Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

22. Successful Treatment of MYC rearrangement Positive Large B Cell Lymphoma Patients with R-CHOP21 Plus Lenalidomide: Results of a Multicenter Phase II HOVON Trial

23. Duohexabody-CD37, a Novel Bispecific Antibody with a Hexamerization-Enhancing Mutation Targeting CD37, Demonstrates Superior Complement-Dependent Cytotoxicity in Preclinical B-Cell Malignancy Models

24. Targeting CD37 in B-Cell Malignancies Using the Novel Therapeutic Duohexabody-CD37 Results in Efficient Killing of Tumor B-Cells Ex Vivo Via Complement-Dependent Cytotoxicity, Even in Relapsed and/or Refractory Patient Samples

26. Myeloid Leukemic Blasts Use the Endogenous HLA Class I Antigen Processing Machinery for Peptide Loading Onto HLA Class II Molecules: Implications for Immunotherapy.

28. TAP- and Proteasome-Dependent Endogenous Antigen Loading of HLA Class II in Leukemic Blasts Introduces a Promising New Target for Generating Leukemia-Specific CD4+ T Cells

Catalog

Books, media, physical & digital resources